| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 728.03% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/09/2023 | 791.72% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 03/29/2023 | 855.41% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/07/2023 | 855.41% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 09/16/2022 | 791.72% | HC Wainwright & Co. | $22 → $14 | Maintains | Buy |
| 09/13/2022 | 218.47% | Piper Sandler | $7 → $5 | Maintains | Overweight |
| 08/29/2022 | 282.17% | Baird | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 1301.27% | HC Wainwright & Co. | $25 → $22 | Maintains | Buy |
| 02/28/2022 | 1492.36% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 12/08/2021 | 1110.19% | Baird | → $19 | Initiates Coverage On | → Outperform |
| 08/10/2021 | 1556.05% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 05/10/2021 | 1492.36% | HC Wainwright & Co. | $27 → $25 | Maintains | Buy |
| 10/22/2020 | 1619.75% | HC Wainwright & Co. | → $27 | Initiates Coverage On | → Buy |
| 10/08/2020 | 1492.36% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 09/18/2020 | 791.72% | Maxim Group | $6 → $14 | Maintains | Buy |
What is the target price for Cardiff Oncology (CRDF)?
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $13.00 expecting CRDF to rise to within 12 months (a possible 728.03% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $14.00 to $13.00. The current price Cardiff Oncology (CRDF) is trading at is $1.57, which is out of the analyst's predicted range.